Exactly one month after participating in the Virtual Summit of the World Federation of Hemophilia (WFH), we are proud to support the 2020 Virtual Congress of the International Society for of Thrombosis and Hemostasis (ISTH) from July 12 to 14.
The main goal of this annual event, which in the year of COVID-19 will take place remotely, is to promote the continuous updating of the international medical-scientific community in the field of research, diagnosis and treatment of Hemophilia and other coagulation disorders, as well as to stimulate discussion on the evolution of a therapeutic area which is undergoing rapid and profound change.
In addition to participating in the event with its own virtual stand, the company will support a scientific symposium, scheduled for Tuesday, July 14, dedicated to reflecting on the present and future role of Factor VIII-based replacement therapy in the treatment of Hemophilia A. The round table, chaired by Pier Mannuccio Mannucci of the Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan (Italy), will host some of the most important international experts in the field: Jerzy Windyga, Director of the Department of Hemostasis Disorders and Internal Medicine of the Institute of Hematology and Transfusion Medicine in Warsaw (Poland); Guy Young, Director of the Center for Hemostasis and Thrombosis of the Children's Hospital of Los Angeles (United States) and Michael Makris, Professor of Hemostasis and Thrombosis of the University of Sheffield (UK).
The prevention and eradication of inhibitors, the induction of immune tolerance and personalized prophylaxis will be the key topics at the center of a symposium organized by Kedrion entitled "Optimizing Patient Care in Hemophilia A: a Critical Appraisal."